PreveCeutical Applies its Proprietary Extraction Protocol for Medical Cannabinoids to Two Additional Cannabis Strains
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in connection with its soluble gel drug delivery research and development program (the "Sol-gel Program"), it has now optimised the conditions for extracting cannabinoids from two additional cannabis strains provided by the Company's licensed producer (LP) partner, Aurora Cannabis Inc. ("Aurora"). The two...
2018-11-05 9:00 AM EST
PreveCeutical Provides Update on Visit to Penta 5 Group's Facility for Due Diligence on Proposed Acquisition
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), provides an update on its recent due diligence trip (the "Due Diligence Trip") to view a facility operated by the Penta 5 group of companies (the "Penta 5 Group") in connection with the Company's proposed acquisition (the "Acquisition") of the Penta 5 Group and its assets (see news release dated October 3, 2018). The Due...
2018-10-31 9:00 AM EDT
PreveCeutical Holds Intensive Workshop to Advance Dual Gene Therapy Research Program for Type 2 Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that its research team at the University of Queensland, recently held a two-day intensive workshop (the "Workshop"), which brought together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth (the "Teams") to collaborate on...
2018-10-30 9:00 AM EDT
PreveCeutical to Visit Penta 5 Group's Packaging Facility for Due Diligence on Proposed Acquisition
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces an update on the Company's due diligence on the Penta 5 group of companies (the "Penta 5 Group"), in connection with the proposed acquisition by the Company of the Penta 5 Group (the "Acquisition") and its assets, which include over seven brands, 40 market-ready products, previously announced on October 3, 2018. To...
2018-10-15 6:30 AM EDT
PreveCeutical Announces LOI to Acquire Penta 5 Health and Wellness Packaging Companies with Market-Ready Products and Production Facilities
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has entered into a letter of intent dated October 1, 2018 (the "LOI") with Penta 5 Packaging Inc. ("Penta 5 Canada") and Penta 5 USA, LLC ("Penta 5 USA" together with Penta 5 Canada and their subsidiaries, the "Penta 5 Group"), both of which are arm's length parties to the Company, with respect to a...
2018-10-03 3:57 PM EDT
PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a Master Services Agreement dated effective October 1, 2018 (the "Agreement") with World Wide Holdings LLC, DBA Invictus Resources ("Invictus"), whereby Invictus will provide investor awareness services (the "Services") to the Company involving the selection and coordination of investor...
2018-09-28 7:25 PM EDT
PreveCeutical Enters into Development Agreement with Asterion Cannabis Inc. to Develop Medicinal Cannabinoid Products
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), and Asterion Cannabis Inc. ("Asterion") announce that they have entered into a development and joint venture agreement (the "Development Agreement") to form a joint venture ("Joint Venture") to develop a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches, and other jointly evaluated products aimed at...
2018-09-26 6:30 AM EDT
PreveCeutical Confirms No Material Change
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), at the request of the Investment Industry Regulatory Organization of Canada (IIROC), confirms that its management is not aware of any undisclosed corporate development or material change to the Company or its operations that would account for the recent increase in market activity. About PreveCeutical PreveCeutical is a...
2018-09-18 4:23 PM EDT
PreveCeutical Develops Proprietary Extraction Protocol for Medical Cannabinoids to be Used with the Sol-gel Drug Delivery Program
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, during its soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), it has successfully optimised the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method for the accurate and precise quantification of cannabinoids...
2018-09-04 9:30 AM EDT
PreveCeutical Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on the Company's progress in its ongoing corporate initiatives. PreveCeutical has recently reached several milestones as it continues to execute its strategy to become a global preventive healthcare company. These milestones include: entering into a natural health product licensing agreement (the...
2018-08-22 9:00 AM EDT
PreveCeutical Signs Agreement with Asterion Cannabis Inc. to License Natural Health Products and Engages Monster Media, LLC to Provide Investor Relations Services
Vancouver, British Columbia--(Newsfile Corp. - August 15, 2018) - PreveCeutical Medical Inc. ("PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada
2018-08-15 9:30 AM EDT
PreveCeutical Announces First Cannabis Product for Treatment of Anxiety
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the first product development program of the Company's newly created medicinal cannabis division is focusing on the development of cannabinoids as a preventive treatment for anxiety disorders using PreveCeutical's nasal delivery, sustained release, Sol-gel ("Sol-gel") delivery platform. For further information on the...
2018-08-08 9:30 AM EDT
PreveCeutical Provides Update on Second Phase of Scorpion Venom-Derived Peptide Program
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on its three phase, scorpion venom-derived peptide research and development program (the "Program"), which consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom, which are a highly complex mixture of peptides, enzymes, mucoproteins, free...
2018-07-31 9:30 AM EDT
PreveCeutical Announces Launch of Cannabis Division
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in keeping with the Company's vision of becoming a global preventive healthcare company, PreveCeutical has launched a medicinal cannabis division (the "Cannabis Division"). The Cannabis Division will be responsible for bringing an array of high-quality, medicinal cannabis-based products to market, and overseeing...
2018-07-24 9:30 AM EDT
PreveCeutical Provides Update on Sol-gel Drug Delivery Program
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on the soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), that involves testing an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The Company's Sol-gel Program uses five distinct Cannabis sativa L....
2018-07-11 9:00 AM EDT
PreveCeutical Retains Link Media LLC to Provide Marketing Services
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announced that it has retained Link Media LLC ("Link Media") to provide communications and market awareness services to the Company, aimed at maintaining and building the profile of PreveCeutical among existing and potential investors. Pursuant to its consulting agreement with PreveCeutical, Link Media will arrange and coordinate...
2018-07-10 12:05 AM EDT
PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the closing of its oversubscribed non-brokered private placement financing previously announced April 9, 2018 (the "Financing"). A total of 130,799,750 units (the "Units") were issued under the Financing at a price of $0.05 per Unit for gross proceeds of $6,539,987.50. Each Unit consists of one common share in the capital...
2018-06-29 10:00 AM EDT
PreveCeutical Announces Oversubscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that based on subscriptions received to date, the Company expects that its $4,000,000 non-brokered private placement (the "Offering") of units at $0.05 (post-forward stock split) announced on April 9, 2018, will be oversubscribed due to higher than expected investor interest. The Company now expects that the Offering will...
2018-06-25 4:01 PM EDT
PreveCeutical Amends Terms of Warrants to Extend Expiry Date
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it will be amending the terms of 20,280,000 (4,076,000 pre-forward stock split) common share purchase warrants (each, a "Warrant") previously issued pursuant to a non-brokered private placement that closed on June 29, 2017. The Warrants were originally exercisable by the holder at a price of $1.00 per common share in...
2018-06-08 5:00 PM EDT
PreveCeutical Engages Stadnyk & Partners to Provide Market Awareness and Strategic Advisory Services
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that is has entered into an agreement with Stadnyk & Partners, whereby it has agreed to engage Stadnyk & Partners to provide strategic advisory services to the Company. The agreement provides that Stadnyk & Partners will provide market awareness services to the Company during the term of the agreement, for which the...
2018-06-05 3:05 AM EDT